Authors: Ahmed R ELNahas Mohamed Tharwat Mohamed Elsaadany Ahmed Mosbah Mohamed A Gaballah
Publish Date: 2015/10/09
Volume: 34, Issue: 7, Pages: 963-968
Abstract
A randomized controlled trial was conducted between January 2013 and July 2014 Inclusion criteria were patients aged 20–50 years who underwent temporary unilateral ureteral stent for drainage of calcular upper tract obstruction or after ureteroscopic lithotripsy Patients with history of lower urinary tract symptoms before stent placement stents that were fixed after open or laparoscopic procedures and those who developed complications related to the primary procedure were not included Eligible patients were randomly assigned to 1 of 3 groups using computergenerated random tables Patients in group 1 received placebo patients in group 2 received tamsulosin 04 mg once daily and those in group 3 received solifenacin 5 mg once daily Ureteral Stent Symptom Questionnaire USSQ was answered by all patients 1–2 weeks after stent placement The primary outcome was the comparison of total score of USSQ between all groupsThe study included 131 patients All baseline characteristics age sex side indication length and duration of stent were comparable for all groups Total USSQ score was 61 in solifenacin group 76 in tamsulosin group and 83 in control group P 0001 The total USSQ scores and all domains except sexual index were significantly better in solifenacin than in tamsulosin group P 005
Keywords: